How will we manage acute HCV in men having sex with men in the era of all oral therapy?

Journal of Viral Hepatitis

Volumn 22, Issue 1, 2014, Pages 2-7

  Boesecke, C ^a   Rockstroh, J K ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Acute hepatitis C; DAA; HIV; MSM

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; BOCEPREVIR; DACLATASVIR; DASABUVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT;

ACUTE HEPATITIS; ACUTE HEPATITIS C; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG SAFETY; HEPATITIS C; HIGH RISK POPULATION; HUMAN; MALE; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; VIRAL CLEARANCE; VIRUS LOAD; DRUG INTERACTION; MALE HOMOSEXUALITY;

ANTIVIRAL AGENTS; DRUG INTERACTIONS; HEPATITIS C; HOMOSEXUALITY, MALE; HUMANS; MALE;

EID: 84924750134     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12348     Document Type: Article

References (52)

1. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014;349:g3308.
2. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2014. J Hepatol 2014;61(2):373-395.
3. Vogel M, Deterding K, Wiegand J et al. Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals: experience from 2 large German networks on the study of acute HCV infection. Clin Infect Dis 2009;49:317-319; author reply 9.
4. Giraudon I, Ruf M, Maguire H et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak? Sex Transm Infect 2008;84:111-115.
5. Gambotti L, Batisse D, Colin-de-Verdiere N et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill 2005;10:115-117.
6. Urbanus AT, van de Laar TJ, Stolte IG et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009;23:F1-F7.
7. Rauch A, Rickenbach M, Weber R et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005;41:395-402.
8. Matthews G, Hellard M, Haber P et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian trial in acute hepatitis C. Clin Infect Dis 2009;48:650-658.
9. Barfod TS, Omland LH, Katzenstein TL. Incidence and characteristics of sexually transmitted acute hepatitis C virus infection among HIV-positive men who have sex with men in Copenhagen, Denmark during four years (2006-2009): a retrospective cohort study. Scand J Infect Dis 2011;43(2):145-148.
10. Sun HY, Chang SY, Yang TY et al. Recent hepatitis C virus infection in HIV-positive patients in Taiwan: incidence and risk factors. J Clin Microbiol 2012;50(3):781-787.
11. van der Helm JJ, Prins M, Del Amo J et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011;25(8):1083-1091.
12. Ghany MG, Strader DB, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-1374.
13. Nelson M, 10th Co-Infection Workshop 2014, June 12-13, Paris, France.
14. McFaul K et al. Acute hepatitis C infection in HIV-negative men who have sex with men. 3rd Joint BHI-VA/BASHH Conference, 3-6 April 2014, Liverpool. Poster abstract 384.
15. Deterding K, Wiegand J, Grüner N et al. The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol 2009;47(6):531-540.
16. Thomson EC, Nastouli E, Main J et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009;23:89-93.
17. The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS. 2011;25(4):399-409.
18. Kubitschke A, Bahr MJ, Aslan N et al. Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. Eur J Clin Invest 2007;37(1):54-64.
19. Soriano V, Mocroft A, Rockstroh J et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008;198:1337-1344.
20. Grebely J, Petoumenos K, Hellard M et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010;52(4):1216-1224.
21. Jones L, Uriel A, Kaplan D et al. Natural history and treatment outcome of acute hepatitis C with and without HIV co-infection in a North American cohort. In: AASLD 2008 Meeting; San Francisco, USA; 2008; abstract 1838.
22. Thomson EC, Fleming VM, Main J et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2011;60(6):837-845.
23. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456.
24. Vogel M, Boesecke C, Rockstroh JK. Acute hepatitis C infection in HIV-positive patients. Curr Opin Infect Dis 2011;24(1):1-6.
25. Vogel M, Page E, Matthews G et al. Use of week 4 HCV RNA after acute HCV infection to predict chronic HCV infection. In: 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, California, USA; 2010; abstract 640.
26. Luetkemeyer A, Hare CB, Stansell J et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr 2006;41:31-36.
27. Fierer D, Fishman S, Uriel A et al. Characterization of an outbreak of acute HCV infection in HIV-infected men in New York city. In: 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; 2009; abstract 802.
28. Gilleece YC, Browne RE, Asboe D et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005;40:41-46.
29. Vogel M, Nattermann J, Baumgarten A et al. Pegylated interferonalpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther 2006;11:1097-1101.
30. Schnuriger A, Dominguez S, Guiguet M et al. ANRS HC EP21 study group. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 2009;23:2079-2089.
31. Dominguez S, Ghosn J, Valantin MA et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006;20:1157-1161.
32. Kruk A. Efficacy of acute HCV treatment with peg-interferon alfa-2b and ribavirin in HIV-infected patients. In: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; Rio de Janeiro; 2005; abstract TuPe1. C01.
33. Serpaggi J, Chaix ML, Batisse D et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006;20:233-240.
34. Piroth L, Larsen C, Binquet C et al. Treatment of acute hepatitis C in human immunodeficiency virusinfected patients: the HEPAIG study. Hepatology 2010;52(6):1915-1921.
35. Arends JE, Lambers FA, van der Meer JT et al. Treatment of acute hepatitis C virus infection in HIV+ patients: dutch recommendations for management. Neth J Med 2011;69(1):43-49.
36. Grebely J, Hellard M, Applegate T et al. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS 2012;26(13):1653-1661.
37. Vogel M, Dominguez S, Bhagani S et al. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort. Antivir Ther 2010;15:267-279.
38. Lambers F, Brinkman K, Schinkel J et al. Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration. AIDS 2011;25(10):1333-1336.
39. Dore GJ, Hellard M, Matthews GV et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010;138(1):123-135.e1-2.
40. Matthews GV, Dore GJ. Optimal duration of treatment for acute hepatitis C in human immunodeficiency virus-positive individuals? Hepatology 2011;53(3):1055-1056; author reply 1056-7.
41. Dorward J, Garrett N, Scott D et al. Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration. J Clin Virol 2011;52(4):367-369.
42. Boesecke C, Rockstroh JK. Treatment of acute hepatitis C infection in HIV-infected patients. Curr Opin HIV AIDS 2011;6(4):278-284.
43. Fierer DS, Dieterich DT, Mullen MP et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis 2014;58(6):873-879.
44. Hullegie S. 10th Co-Infection Workshop 2014, #O-02
45. Boesecke C. Acute HCV Treatment - European Perspective. International HIV/Viral Hepatitis Co-Infection Satellite Meeting, July 18-19 2014, Melbourne, Australia.
46. Franco S, Tural C, Nevot M et al. Detection of a Sexually Transmitted Hepatitis C Virus Protease Inhibitor-Resistance Variant in a Human Immunodeficiency Virus-Infected Homosexual Man. Gastroenterology 2014;147:599-601.
47. Rockstroh J, Grint D, Boesecke C et al. Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected? J Int AIDS Soc, 2012;15(Suppl. 4):18116 Oral Abstract - O242.
48. Ingiliz P, Krznaric I, Stellbrink HJ et al. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. HIV Med 2014;15(6):355-361.
49. Boesecke C, Ingiliz P, Mandorfer M. Is there Long-term Evidence of Advanced Liver Fibrosis after Acute Hepatitis C in HIV Coinfection? Conference on Retrovirus and Opportunistic Infections (CROI), March 3-6 2014, Abstract#1396, Poster #644.
50. Martin NK, Vickerman P, Foster GR et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011;54(6):1137-1144.
51. Martin NK, Vickerman P, Goldberg D, Hickman M. HCV treatment as prevention in prison: key issues. Hepatology. 2014 May 3. doi: 10. 1002/hep. 27194. [Epub ahead of print].
52. Wedemeyer H, Duberg AS, Buti M et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014;21(Suppl. 1):60-89.